Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis
Comparison of Rebif Compared to Tecifdera on Six-month Outcomes in Patients With Relapsing-remitting MS
|3||Active, not recruiting||
Pharmacokinetics of DMF and the Effects of DMF on Exploratory Biomarkers
† Study has passed its completion date and status has not been verified in more than two years.